Target- |
MechanismMuscle relaxation antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date25 Jul 2008 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date07 Apr 2005 |
|
MechanismGnRHR antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date29 Jul 1999 |
100 Clinical Results associated with Merck Sharp & Dohme Farmaceutica Ltda.
0 Patents (Medical) associated with Merck Sharp & Dohme Farmaceutica Ltda.
100 Deals associated with Merck Sharp & Dohme Farmaceutica Ltda.
100 Translational Medicine associated with Merck Sharp & Dohme Farmaceutica Ltda.